Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Summary

A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk, myelodysplastic syndrome (MDS). Once the highest safe dose is found, researchers will then try to learn if this combination treatment can help control AML and high-risk MDS in newly diagnosed patients. The safety of this treatment combination will also be studied.

Timeline

Start

2007-10

Primary completion

2011-05

Completion

2011-05

Drugs

Indications